A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)
Miguel Martín(Hospital General Universitario Gregorio Marañón), A. Chan(Curtin University), Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Joyce O’Shaughnessy(Texas Oncology), Roberto Hegg(Hospital da Mulher São Paulo), Alexey Manikhas(City Clinical Oncology Center), Mikhail Shtivelband(Ironwood Pharmaceuticals (United States)), Petr Krivorotko(Institute of Oncology NN Petrov), Norberto Batista López(Hospital Universitario de Canarias), Mario Campone(Institut de Cancérologie de l'Ouest), Manuel Ruíz Borrego(Hospital Universitario Virgen del Rocío), Qamar J. Khan(University of Kansas Medical Center), Julia Beck(Highlands Oncology Group), Manuel Ramos Vázquez(Centro Oncológico de Galicia), Patrick Urban(Novartis (Switzerland)), S Goteti(Novartis (Switzerland)), Emmanuelle di Tomaso(Novartis (United States)), Cristian Massacesi(Novartis (France)), Suzette Delaloge(Institut Gustave Roussy)
Cited by 185Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis